首页 > 市场调查报告书 > 製药

药物开发

市场调查报告书

商品编码

1471953

药物发现资讯学市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按工作流程、服务、解决方案、最终用户和地理位置

Drug Discovery Informatics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Workflow, Service, Solution, End User, and Geography

出版日期: 2024年03月18日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

2023年药物发现资讯学市场价值为30.7亿美元，预计到2031年将达到81.7亿美元；预计2023-2031年复合年增长率为13.0%。

推动市场成长的关键因素是製药公司对新药分子研发的投资不断增加，以及药物发现和开发中计算和资讯工具的日益采用。然而，熟练技术人员的缺乏和软体安装成本高昂阻碍了药物发现资讯学市场的成长。

药物发现资讯学市场的市场趋势：

在药物开发和发现中部署人工智慧和机器学习 (ML) 演算法，透过提高这些过程的效率、速度和成功率，正在彻底改变药物开发。这些技术用于分析大量资料、识别模式、预测分子相互作用并加速新候选药物的发现。将人工智慧融入资讯科学所带来的优势大大增加了对计算工具、演算法和资料库的需求，以发现和开发新的药物分子。此外，医疗保健技术製造商正在市场上推出各种人工智慧整合解决方案；这对不断增长的药物发现资讯学市场规模做出了积极贡献。例如，根据该公司新闻稿，默克于 2023 年 12 月推出了 AIDDISON 药物发现软体，这是一种结合药物发现和合成的创新人工智慧解决方案。它是第一个软体即服务平台，透过 Synthia 逆合成软体 API 整合将虚拟分子设计和现实可製造性联繫起来。

此外，领先的科技公司正在与学术机构合作开发用于药物发现的资讯技术。例如，2023年1月，日立高新技术解决方案公司宣布与庆应义塾大学药学院药学系合作进行联合研究，利用材料资讯学（MI）提高小分子药物的开发效率。该团队将利用化学资讯学（CI）MI工具开发传统化学材料领域的材料以及药物发现，以提高人们的生活品质（QoL）。

因此，药物发现和产品发布方面的技术进步预计将在未来几年带来新的药物发现资讯学市场趋势。

药物发现资讯学市场：细分概述

肿瘤生物相似药根据药物类别、癌症类型和配销通路进行细分。

根据工作流程，市场分为发现资讯学和药物开发。发现资讯学领域在2023 年占据了更大的市场份额。。这对社会产生了显着影响，特别是在寨卡病毒和武汉病毒爆发等国家和国际灾难期间。由于接触当前技术，资讯学工具和资料库预计在未来几年将大幅扩展。这些技术对于帮助公共卫生部门寻找新疗法至关重要，而新疗法预计将推动药物发现资讯学市场的成长。

依服务划分，市场分为序列分析平台、分子建模、临床试验资料管理、对接等。序列分析平台领域预计将在 2023 年占据最大的市场份额。

根据解决方案，药物发现资讯学市场分为软体和服务。到 2023 年，服务细分市场将占据更大的药物发现资讯学市场份额，预计 2023 年至 2031 年该细分市场的复合年增长率将更高。

根据最终用户，市场分为製药和生物技术公司、合约研究组织等。製药和生物技术公司细分市场在 2023 年占据最大市场份额。

药物发现资讯学市场：地理概述

药物发现资讯学市场报告的范围涉及北美（美国、加拿大和墨西哥）、欧洲（西班牙、英国、德国、法国、义大利和欧洲其他地区）、亚太地区（韩国、中国、印度、日本、澳洲和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地区）。预计 2023 年至 2031 年，亚太地区的药物发现资讯学市场复合年增长率最快。这是由于 Charles River Laboratories、Certara 和 Curia 等主要参与者的存在、传染病的高发生率以及领先製药公司和合约研究组织 (CRO) 快速采用新的先进研发工具等因素造成的。和开发。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 12 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第13章：竞争格局

关键参与者的热图分析
公司定位与专注

第 14 章：药物发现资讯学市场 - 主要公司概况

Certara
Infosys Ltd
Collaborative Drug Discovery, Inc
Jubliant Biosys
Curia Global, Inc
Chemaxon Ltd
Charles River Laboratories
Agilent Technologies, Inc
Illumina, Inc
Boehringer Ingelheim International GmbH
Evotec

第 15 章：附录

简介目录

Product Code: TIPHE100000965

The Drug discovery informatics market was valued at US$ 3.07 billion in 2023 and is expected to reach US$ 8.17 billion by 2031; it is estimated to record a CAGR of 13.0% during 2023-2031.

Key factors driving the market growth are the increasing investments in the R&D of new drug molecules by pharmaceutical companies and the growing adoption of computational and information tools for drug discovery and development. However, the dearth of skilled technicians and the high cost of software setup hinder the drug discovery informatics market growth.

Market Trends of the Drug Discovery Informatics Market:

The deployment of AI and machine learning (ML) algorithms in drug development and discovery are revolutionizing drug development by enhancing these processes' efficiency, speed, and success rates. These technologies are used to analyze vast amounts of data, identify patterns, predict molecular interactions, and accelerate the discovery of novel drug candidates. The advantages offered by incorporating AI in informatics sciences have surged the demand for computational tools, algorithms, and databases to discover and develop new drug molecules. Additionally, healthcare technology manufacturers are launching various AI-integrated solutions in the market; this is positively contributing to the growing drug discovery informatics market size. For instance, as per the company press release, in December 2023, Merck introduced AIDDISON drug discovery software, an innovative AI solution that combines drug discovery and synthesis. It is the first software-as-a-service platform that bridges virtual molecule design and real-world manufacturability through Synthia retrosynthesis software API integration.

Additionally, leading tech companies are collaborating with academic institutions to develop information technology for drug discovery. For instance, in January 2023, Hitachi High-Tech Solutions Corporation announced the partnership with Keio University Faculty of Pharmacy, Department of Pharmaceutical Sciences, to conduct joint research that will use Materials Informatics (MI) to enhance the efficiency of developing small molecule drugs. The team will leverage the Chemicals Informatics (CI) MI tool for developing materials in the traditional chemical materials field and also in drug discovery, with a view to improving the Quality of Life (QoL) for people.

Thus, such technological advancements in drug discovery and product launches are anticipated to bring new drug discovery informatics market trends in the coming years.

Drug Discovery Informatics Market: Segmental Overview

The oncology biosimilars are segmented based on drug class, cancer type, and distribution channel.

By workflow, the market is bifurcated into discovery informatics and drug development. The discovery informatics segment held a larger market share in 2023. The drug development segment is projected to register a higher CAGR from 2023 to 2031. The deployment of informatics tools and databases has significantly reduced the time to market for new therapies. This has remarkably impacted society, especially during national and international disasters, such as the Zika and Wuhan virus outbreaks. As a result of exposure to current technology, informatics tools, and databases are expected to expand enormously in the coming years. These technologies will be essential in helping the public health sector find novel therapies, which, in turn, is anticipated to propel the drug discovery informatics market growth.

The market, by service, is segmented into sequence analysis platforms, molecular modeling, clinical trial data management, docking, and others. The sequence analysis platform segment is anticipated to hold the largest market share in 2023. The molecular modeling segment is projected to register the highest CAGR from 2023 to 2031.

By solution, the drug discovery informatics market is segmented into software and services. The services segment held a larger drug discovery informatics market share in 2023, and the same segment is projected to register a higher CAGR from 2023 to 2031.

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2023. The contract research organizations segment is expected to register the highest CAGR from 2023 to 2031.

Drug Discovery Informatics Market: Geographical Overview

The scope of the drug discovery informatics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the Drug discovery informatics market from 2023-2031. This is attributed to factors such as the presence of major players, including Charles River Laboratories, Certara, and Curia, the high incidence of infectious diseases, and the rapid adoption of new and advanced R&D tools by leading pharmaceutical companies and Contract Research Organizations (CROs) for drug discovery and development.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Drug Discovery Informatics Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Drug Discovery Informatics Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Drug Discovery Informatics Market - Global Market Analysis

6.1 Drug Discovery Informatics - Global Market Overview
6.2 Drug Discovery Informatics - Global Market and Forecast to 2031

7. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By Workflow, 2021-2031

7.1 Overview
7.2 Discovery Informatics
7.3 Drug Development

8. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By Service, 2021-2031

8.1 Overview
8.2 Sequence Analysis Platform
8.3 Molecular Modeling
8.4 Clinical Trial Data Management
8.5 Docking
8.6 Others

9. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By Solution, 2021-2031

9.1 Overview
9.2 Software
9.3 Services

10. Drug Discovery Informatics Market - Revenue Analysis (USD Million) - By End User, 2021-2031

10.1 Overview
10.2 Pharmaceutical and Biotechnology Companies
10.3 Contract Research Organizations
10.4 Others

11. Drug Discovery Informatics Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

11.1 North America
- 11.1.1 North America Drug Discovery Informatics Market Overview
- 11.1.2 North America Drug Discovery Informatics Market Revenue and Forecasts to 2031
- 11.1.3 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Workflow
- 11.1.4 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Service
- 11.1.5 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Solution
- 11.1.6 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By End User
- 11.1.7 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Drug Discovery Informatics Market
    - 11.1.7.1.1 United States Drug Discovery Informatics Market, by Workflow
    - 11.1.7.1.2 United States Drug Discovery Informatics Market, by Service
    - 11.1.7.1.3 United States Drug Discovery Informatics Market, by Solution
    - 11.1.7.1.4 United States Drug Discovery Informatics Market, by End User
  - 11.1.7.2 Canada Drug Discovery Informatics Market
    - 11.1.7.2.1 Canada Drug Discovery Informatics Market, by Workflow
    - 11.1.7.2.2 Canada Drug Discovery Informatics Market, by Service
    - 11.1.7.2.3 Canada Drug Discovery Informatics Market, by Solution
    - 11.1.7.2.4 Canada Drug Discovery Informatics Market, by End User
  - 11.1.7.3 Mexico Drug Discovery Informatics Market
    - 11.1.7.3.1 Mexico Drug Discovery Informatics Market, by Workflow
    - 11.1.7.3.2 Mexico Drug Discovery Informatics Market, by Service
    - 11.1.7.3.3 Mexico Drug Discovery Informatics Market, by Solution
    - 11.1.7.3.4 Mexico Drug Discovery Informatics Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe
- 11.2.1 Germany
- 11.2.2 France
- 11.2.3 Italy
- 11.2.4 Spain
- 11.2.5 United Kingdom
- 11.2.6 Rest of Europe
11.3 Asia-Pacific
- 11.3.1 Australia
- 11.3.2 China
- 11.3.3 India
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
- 11.4.1 South Africa
- 11.4.2 Saudi Arabia
- 11.4.3 U.A.E
- 11.4.4 Rest of Middle East and Africa
11.5 South and Central America
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Rest of South and Central America

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. Drug Discovery Informatics Market - Key Company Profiles

14.1 Certara
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies